Aprea Therapeutics's three largest insider shareholders as of March 23, 2026 are Oren Gilad (President/Ceo, 373.72K shares), Christian S Schade (Director, 259.25K shares), Marc Duey (Director, 256.15K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Oren Gilad | President/Ceo | 393,895 | 0 | 16 Mar, 2026 |
| Christian S Schade | 259,246 | 0 | 01 Aug, 2022 | |
| Marc Duey | 256,155 | 0 | 11 Dec, 2025 | |
| Scott M Coiante | Svp, Chief Financial Officer | 145,065 | 0 | 01 Aug, 2022 |
| Eyal C. Attar | Svp, Chief Medical Officer | 57,233 | 0 | 07 Jun, 2022 |
| Bernd R. Seizinger | 45,775 | 0 | 09 Jun, 2025 | |
| Gregory Alan Korbel | Svp, Chief Operating Officer | 45,762 | 0 | 01 Aug, 2022 |
| John P. Hamill | Srvp/Cfo/Prin Fin Acct Ofcr | 43,528 | 0 | 16 Mar, 2026 |
| John B Iii Henneman | 10,229 | 0 | 09 Jun, 2025 | |
| Nadeem Q. Mirza | Chief Medical Officer | 6,730 | 0 | 02 May, 2024 |
| Rifat Pamukcu | 5,446 | 0 | 09 Jun, 2025 | |
| Fouad Namouni | 4,610 | 0 | 01 Jul, 2021 | |
| Michael Aaron Kelly | 4,610 | 0 | 01 Jul, 2021 | |
| Richard Peters | 3,119 | 0 | 09 Jun, 2025 | |
| Michael Grissinger | 2,889 | 0 | 09 Jun, 2025 | |
| Jean-Pierre Bizzari | 1,045 | 0 | 09 Jun, 2025 | |
| Gabriela Gruia | 1,045 | 0 | 09 Jun, 2025 | |
| Marc Duey | 0 | 602 | 24 Aug, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Mar, 2026 | John P. Hamill | Common Stock | A | 10,095 | $0.00 | 43,528 | D | A |
| 12 Mar, 2026 | Oren Gilad | Common Stock | A | 20,175 | $0.00 | 393,895 | D | A |
| 12 Mar, 2026 | John P. Hamill | Stock Options (Right to Buy) | A | 40,380 | $0.00 | 40,380 | D | A |
| 12 Mar, 2026 | Oren Gilad | Stock Options (Right to Buy) | A | 80,700 | $0.00 | 80,700 | D | A |
| 30 Jan, 2026 | John P. Hamill | Common Stock | A | 5,700 | $0.89 | 33,433 | D | P |
| 30 Jan, 2026 | Oren Gilad | Common Stock | A | 28,100 | $0.89 | 373,720 | D | P |
| 30 Jan, 2026 | John P. Hamill | Common Warrant | A | 5,700 | - | 5,700 | D | P |
| 30 Jan, 2026 | Oren Gilad | Common Warrant | A | 28,100 | - | 28,100 | D | P |
| 10 Dec, 2025 | John P. Hamill | Common Stock | A | 5,000 | $1.17 | 27,733 | D | P |
| 10 Dec, 2025 | Marc Duey | Common Stock | A | 21,459 | $1.17 | 256,155 | D | P |
| 10 Dec, 2025 | John P. Hamill | Common Warrant | A | 5,000 | - | 5,000 | D | P |
| 10 Dec, 2025 | Marc Duey | Common Warrant | A | 21,459 | - | 21,459 | D | P |
| 10 Dec, 2025 | Oren Gilad | Pre-Funded Warrant | A | 21,459 | $1.17 | 21,459 | D | P |
| 10 Dec, 2025 | Oren Gilad | Common Warrants | A | 21,459 | - | 21,459 | D | P |
| 05 Jun, 2025 | Richard Peters | Common Stock | A | 1,045 | $0.00 | 3,119 | D | A |
| 05 Jun, 2025 | Marc Duey | Common Stock | A | 1,045 | $0.00 | 234,696 | D | A |
| 05 Jun, 2025 | Jean-Pierre Bizzari | Common Stock | A | 1,045 | $0.00 | 1,045 | D | A |
| 05 Jun, 2025 | Rifat Pamukcu | Common Stock | A | 1,045 | $0.00 | 5,446 | D | A |
| 05 Jun, 2025 | Gabriela Gruia | Common Stock | A | 1,045 | $0.00 | 1,045 | D | A |
| 05 Jun, 2025 | John B Iii Henneman | Common Stock | A | 1,045 | $0.00 | 10,229 | D | A |